Infectious tolerance describes an in vivo process in which tolerance is passed on from one population of lymphocytes to another. In this way, short-term therapy aimed at generating infectious tolerance has the potential to achieve long term, self-perpetuating immune homeostasis in a clinical setting. In recent years, a number of differing strategies have successfully achieved tolerance in vivo. These include harnessing regulatory T cells and tolerogenic antigen presenting cells, promoting tolerogenic interactions or inhibiting activation of effector cells. Many of these are just beginning to face the harsh realities of the therapeutics industry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.coi.2010.08.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know.
Pharmaceutics
December 2024
Clinical Pharmacology Unit, San Giovanni di Dio e Ruggi d'Aragona University Hospital, 84131 Salerno, Italy.
Highly active antiretroviral therapy has led to a significant increase in the life expectancy of people living with HIV. The trade-off is that HIV-infected patients often suffer from comorbidities that require additional treatment, increasing the risk of Drug-Drug Interactions (DDIs), the clinical relevance of which has often not been determined during registration trials of the drugs involved. Therefore, it is important to identify potential clinically relevant DDIs in order to establish the most appropriate therapeutic approaches.
View Article and Find Full Text PDFEffect of L. on Improving Insulin Secretory Capacity and Resistance in Elderly Patients Aged 80 Years Old or Older Who Develop Diabetes After COVID-19 Infection.
Nutrients
January 2025
Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima City 960-1295, Fukushima, Japan.
(1) Background: It has been reported that people affected by COVID-19, an infectious disease caused by SARS-CoV-2, suffer from various diseases, after infection. One of the most serious problems is the increased risk of developing diabetes after COVID-19 infection. However, a treatment for post-COVID-19 infection diabetes has not yet been established.
View Article and Find Full Text PDFProtection Conferred by Gallid Alphaherpesvirus 2 Vaccines Against Immunosuppression Induced by Very Virulent Plus (vv+) Marek's Disease Virus Strains in Commercial Meat Type Chickens.
Pathogens
January 2025
College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA.
Very virulent plus Marek's disease virus (vv+MDV) induces severe immunosuppression in commercial chickens. In this study, we evaluated how three Gallid alphaherpesvirus 2 (GaHV-2) vaccines (CVI-988, rMd5-BAC∆Meq, and CVI-LTR) protected against two negative outcomes of vv+MDV infection: (1) reduced viability and frequency of immune cells in the spleen and (2) decreased efficacy of the CEO (chicken embryo origin) vaccine against infectious laryngotracheitis challenge. At 25 days post-infection with vv+MDV 686, all vaccines are protected against the reduced viability of splenocytes.
View Article and Find Full Text PDFGrowth Characteristics of Sheep-Derived and Preliminary Research on Effects in Mice and Lambs.
Microorganisms
January 2025
College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
With the growing demand for sheep, the sheep farming industry has developed rapidly. However, lamb diarrhea, a disease with high mortality rates, significantly hampers the industry's growth. Traditional antibiotic treatments often disrupt the Intestinal microbiota, induce antibiotic resistance, and cause adverse side effects, highlighting the urgent need to develop alternative therapies.
View Article and Find Full Text PDFUsing Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study.
Antibiotics (Basel)
January 2025
Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161 Rome, Italy.
: Obesity is an established risk factor for several infective conditions, including Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), with a rising trend in their incidence expected in this population. Although numerous antibiotics are available for the prevention and treatment of ABSSSIs, their characterization in obese patients is not a regulatory mandate, highlighting a knowledge gap in this field. Dalbavancin (DAL) is the first approved long-acting antibiotic for the treatment of ABSSSIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!